載入...
The frequency and availability of population-specific patient reported outcome measures and minimal clinically important differences among approved drugs in Canada
BACKGROUND: Patient reported outcome measures (PROMs) and minimal clinically important differences (MCIDs) are included in Canada’s Common Drug Review (CDR) process to approve new drugs. Often, the measures report on the health-related quality of life (HRQoL), but can also describe the symptoms, eff...
Na minha lista:
| 發表在: | Health Qual Life Outcomes |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6322322/ https://ncbi.nlm.nih.gov/pubmed/30616654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12955-018-1070-0 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|